In Vivo Infographics
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Infographic: In Vivo explores trends in personalized medicine, looking at the 25 new molecular entities approved in the US last year with an individualized aspect.
AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.
In 2018, the 15 biggest pharma companies paid their CEOs $256m in total compensation, 2% more than they received in 2017. Find out who got paid the most, how much R&D leaders received and how median employee pay measured up, while comparing company performance.
Infographic: Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair (and high) prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries.
Exploring route of administration, mode of action, clinical trial, and therapy area trends across the biopharma pipeline.
Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.
The world of health care has become much connected thanks to the venture capital that has already poured into health-related social media structures and the Internet-Of-Things. People are connected to sensors, devices are connected to phones, and patients are connected to physicians. The latecomers – pharmaceutical and medtech firms – can now plug in to this partly-formed network both through direct investment and their strategic venture funds.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.